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Metronidazole was until recently used as a first-line treatment for potentially life-threatening
Clostridioides difficile (CD) infection. Although cases of metronidazole resistance have been
documented, no clear mechanism for metronidazole resistance or a role for plasmids in
antimicrobial resistance has been described for CD. Here, we report genome sequences of
seven susceptible and sixteen resistant CD isolates from human and animal sources,
including isolates from a patient with recurrent CD infection by a PCR ribotype (RT)
020 strain, which developed resistance to metronidazole over the course of treatment
(minimal inhibitory concentration [MIC]= 8mg L−1). Metronidazole resistance correlates
with the presence of a 7-kb plasmid, pCD-METRO. pCD-METRO is present in toxigenic and
non-toxigenic resistant (n= 23), but not susceptible (n= 563), isolates from multiple
countries. Introduction of a pCD-METRO-derived vector into a susceptible strain increases
the MIC 25-fold. Our finding of plasmid-mediated resistance can impact diagnostics and
treatment of CD infections.
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C lostridioides difficile (Clostridium difficile) is a Gram-positive obligate anaerobe capable of causing Clos-tridioides difficile Infection (CDI) upon disruption of the
normal intestinal microbiota1. Although it is one of the major
causes of nosocomial infectious diarrhea, community-acquired
CDI is becoming more frequent2,3. CDI infection poses a sig-
nificant economic burden with an estimated cost at €3 billion per
year in the European Union and impairs the quality of life in
infected individuals4,5. The incidence of CDI has increased over
the last two decades with outbreaks caused by epidemic types
such as PCR ribotype (RT) 027 (NAP1/BI)6. CDI is not restricted
to this type, however, as infections caused by RT001, RT002,
RT014/020, and RT078 are frequently reported in both Europe
and the United States7,8. Metronidazole is used for the treatment
of mild-to-moderate infections and vancomycin for severe
infections, though vancomycin is increasingly indicated as a
general first-line treatment9–16. Fidaxomicin has recently also
been approved for CDI treatment, but its use is limited by high
costs12. Fecal microbiota transplantation (FMT) is effective at
treating recurrent CDI (rCDI) that is refractory to antimicrobial
therapy17. Reduced susceptibility and resistance to clinically used
antimicrobials, including metronidazole, has been reported and
this, combined with the intrinsic multiple drug-resistant nature of
C. difficile, stresses the importance for the development of better
diagnostics and new effective treatment modalities8.
Routine antimicrobial susceptibility testing is generally not
performed for C. difficile and consequently, reports of resistance
to metronidazole are rare18–20. Longitudinal surveillance in
Europe found that 0.2% of clinical isolates investigated were
resistant to metronidazole19, but reported rates from other studies
vary from 0 to 18.3%21–24. These differences may reflect geo-
graphic distributions in resistant strains, or differences in testing
methodology and breakpoints used25,26. Moreover, metronida-
zole resistance can be unstable, inducible and heterogeneous27.
Finally, metronidazole resistance appears to be more frequent in
non-toxigenic strains such as those belonging to RT010, which
have a 7–9-fold increase in Minimal Inhibitory Concentration
(MIC) values compared to RT001, RT027 and RT07821,26.
Metronidazole is a 5-nitroimidazole prodrug that upon intra-
cellular reductive activation induces cellular damage through
nitro-radicals27. It is not only used in the treatment of CDI, but
also an important drug for treating parasitic infections and as
prophylactic antimicrobial in for instance abdominal surgery27,28.
Mechanisms associated with metronidazole resistance described
in other organisms include the presence of 5-nitroimidazole
reductases (nim genes), altered pyruvate-ferredoxin oxidor-
eductase (PFOR) activity and adaptations to (oxidative) stress27.
The knowledge on resistance mechanisms in C. difficile is very
limited, but may involve modulation of core metabolic and stress
pathways as well29,30. Of note, levels of metronidazole achieved in
the colon are generally low and this could be relevant for the
selection of resistant strains31.
Here, we present a case of a patient with rCDI due to an
initially metronidazole susceptible (MTZS) RT020 strain, which
developed resistance to metronidazole over time. We analyze the
genome sequences of these toxigenic MTZS and metronidazole-
resistant (MTZR) strains, together with 5 MTZS and 11 MTZR
non-toxigenic RT010 strains. We identify pCD-METRO, a 7-kb
plasmid conferring metronidazole resistance. This plasmid is
internationally disseminated and also occurs in epidemic types.
We thus report a clinically relevant phenotype associated with
plasmid carriage in C. difficile.
Results
In-patient development of a metronidazole-resistant strain. A
54-year-old kidney–pancreas transplant patient with a medical
history of Type I diabetes mellitus, vascular disease and a double
lower-leg amputation was on hemodialysis when developing
diarrhea. The patient was subsequently diagnosed with CDI and a
toxigenic metronidazole sensitive (MIC= 0.25 mg L−1) RT020
strain was isolated from the fecal material of the patient. Treat-
ment with metronidazole was started, leading to initial resolution
of the symptoms (Fig. 1). Two more episodes of CDI occurred
during which the patient was treated primarily with vancomycin
(but also metronidazole) prior to an FMT provided by the
Netherlands Donor Feces Bank. At the start of the second episode
a MTZS RT020 strain was once more isolated.
Three months after the first FMT, the patient once again
developed bloody diarrhea and two more episodes of rCDI were








C. difficile strain PCR ribotype, metronidazole susceptible
C. difficile strain PCR ribotype, metronidazole resistant
Clinical information other than antibiotics. 
Fig. 1 Timeline of the course of the antibiotic treatment and rCDI in the patient. Dates and timepoints on which treatment was initiated or stopped and C.
difficile isolates were recovered are indicated above the timeline. (r)CDI was diagnosed when both a toxin enzyme-immune assay and nucleic acid
amplification test were positive for C. difficile in combination with a physician’s assessment of symptoms consistent with CDI. Yellow highlighting indicates
the time where pCD-METRO-positive MTZR C. difficile was isolated. Source data are provided as a Source Data file.
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fidaxomicin regime. At two instances, RT020 strains were again
isolated from the fecal material of the patient. Strikingly, these
two clinical isolates were now phenotypically resistant to
metronidazole (MIC= 8 mg L−1 as determined by agar dilution).
Ultimately the patient was cured by a second FMT.
We hypothesized that the rCDI episodes were due to clonal
RT020 strains that persisted despite antimicrobial therapy and an
FMT. Clonal MTZS and MTZR strains would allow us to
determine the underlying genetic changes that resulted in
metronidazole resistance. To determine the relatedness between
these RT020 isolates whole-genome sequencing (WGS) was
performed (Table 1). We also included two more MTZR
RT020 strains and a non-related RT078 strain isolated from the
same patient and 4 MTZS and 8 MTZR RT010 strains from our
laboratory collection (Supplementary Data 1) to perform single-
nucleotide polymorphism (SNP) analyses. Strains were consid-
ered resistant to metronidazole with MIC values >2 mg L−1
according to the EUCAST epidemiological cutoff value32. All
strains resistant to metronidazole (n= 12) showed cross-
resistance to the nitroimidazole drug tinidazole.
Assembly of the MTZR RT020 strain IB136 (Supplementary
Data 2) resulted in a genome of 4166362 bp with 57 contigs, and
an average G+C-content of 28.5% (N50= 263391 bp, mapping
rate 98.97%). A BLAST comparison between this genome and the
NCBI nt database showed that the genome is closest to the
genome of strain LEM133. As expected, 5/6 strains isolated from
the patient (all RT020) showed 100% identity over the majority of
all contigs, suggesting they are highly similar. All RT020 strains
were found to be of multi-locus sequence type (ST) 2, consistent
with data from others34. The sixth strain (IB137), was a clear
outlier and was identified as being closest to the RT078 reference
strain M12035. This is consistent with another ribotype (RT078)
and sequence type (ST11) assignment. All RT010 strains belonged
to ST15.
Resistance does not correlate with a SNP. Previous studies
analyzing the mechanism behind metronidazole resistance in
C. difficile only studied a single isolate each29,36. We performed a
core genome SNP analysis on selected strains (n= 18; Table 1),
comparing MTZS (n= 6) and MTZR (n= 12) strains within and
between the different PCR ribotypes (RT010, RT020 and RT078).
The evolutionary rate of C. difficile has been estimated at 0–2
SNPs per genome per year, but might vary based on intrinsic
(strain type) and extrinsic (selective pressure) factors37. Our
analysis identified a single SNP in the MTZR RT020 (IB136),
compared to the MTZS RT020 strains derived from the same
patient, conclusively demonstrating that these strains are clonal.
Considering the time of isolation of the susceptible and resistant
isolates, this implies the MTZS RT020 strain most likely acquired
metronidazole resistance. In contrast, between the MTZS and MTZR
RT010 isolates (which come from diverse human and animal
sources) 457 SNPs were detected. Moreover, RT010 and RT020
were separated by >25,000 SNPs.
The SNP identified in the RT020 strains discriminating the
MTZS from the MTZR isolates is located in a conserved putative
cobalt transporter (CbiN, IPR003705). However, the SNP is not
observed in the MTZR RT010 strains. Thus, metronidazole
resistance is either multifactorial or not contained within the core
genome. We did not investigate the contribution of this SNP to
metronidazole resistance further.
MTZR C. difficile strains contain a 7-kb plasmid. Next, we
investigated extrachromosomal elements (ECEs), which can include
plasmids. Although plasmids containing antimicrobial resistance
determinants have been described in Gram-positive bacteria, they
appear to be more common in Gram-negatives38. Plasmids in
C. difficile are known to exist, but no phenotypic consequences of
plasmid carriage have been described to date39. The investigation
of the pan-genome of all sequenced strains, including a prediction
of ECEs predicted by an in-house pipeline similar to
PLACNET40,41, showed a single contig that was present in all
MTZR strains (4.6–19.27% of reads mapped, with a minimum of
479497), but absent from MTZS strains, of both RT010 and
RT020 (0% of reads mapped with a maximum 327 reads). Cir-
cularization based on terminal repeats yielded a putative plasmid
of 7056 bp with a G+C-content of 41.6% (Fig. 2a). Correct
assembly was confirmed by PCR (Fig. 2b) and Sanger sequencing.
To confirm the circular nature of the contig, total DNA isolated
from the MTZR RT010 strain IB138 before and after PlasmidSafe
DNase (PSD, Epicenter)39 treatment was analyzed by PCR using
primers specific for chromosomal DNA (gluD) and the putative
plasmid (Fig. 2c). A positive signal for gluD was only observed in
samples that had not been treated with PSD, demonstrating that
PSD treatment degrades chromosomal DNA to below the
detection limit of the PCR. By contrast, a signal specific for the
putative plasmid was visible both before and after PSD treatment.
Consequently, we conclude that our whole-genome sequence
identified a legitimate 7-kb plasmid.
A total of eight open-reading frames (ORFs) were annotated
on the plasmid (Fig. 2a). ORF1-5 encode a hypothetical protein
(ORF1), a MobC-like relaxase/Arc-type ribbon-helix-helix
(ORF2; PF05713), a MobA/VirD2 family endonuclease relaxase
protein (ORF3; PF03432), a hypothetical protein with a
MutS2 signature (ORF4), and a predicted replication protein
(ORF5), respectively. ORF6 is a small ORF that is likely a
pseudogene, and the remaining ORFs encode a metallohydrolase/
oxidoreductase protein (ORF7; IPR001279) and a Tn5-like
transposase gene (ORF8; PF13701). Intriguingly, ORF6 showed
homology on the protein level to the 5-nitroimidazole reductase
(nim) gene nimB (33% identity, 54% positives over 61 amino
acids) described in Bacteroides fragilis (CAA50578.1) and found
in both metronidazole-resistant and susceptible isolates of
anaerobic Gram-positive cocci.42,43 The ORF lacks the region
encoding the N-terminal part of the Nim protein, and the
Phyre2-predicted protein structure shows it lacks the catalytic site
residues. Of note, the plasmid sequences from all strains are
highly similar. Compared to the plasmid of strain IB136, only
strains IB143, IB144, and IB145 contained a single SNP resulting
in a Y286S mutation within the Tn5-like transposase ORF
(Supplementary Fig. 1).
Altogether, these results show that all of the MTZR strains, but
none of the MTZS strains, sequenced in this study contain a
plasmid, hereafter referred to as pCD-METRO (for plasmid from
C. difficile associated with metronidazole resistance).
pCD-METRO is found in strains from different countries. Two
clinical isolates with stable metronidazole resistance have been
described and we evaluated the presence of pCD-METRO in the
assembled genome sequences from these strains using
BLAST29,36. We failed to identify pCD-METRO in the draft
genome of a toxigenic NAP1 isolate that acquired stable metro-
nidazole resistance through serial passaging under selection36. We
did identify pCD-METRO (fragmented over multiple contigs) in
the draft genome a non-toxigenic Spanish RT010 strain with
stable metronidazole resistance (strain 7032989), whereas neither
the reduced-susceptible strain nor the susceptible strain from the
same study contained the plasmid29. We confirmed these results
using PCR, as described for strain IB138 (Fig. 3; lanes SP),
demonstrating pCD-METRO is indeed present in strain 7032989.
These data show that the presence of pCD-METRO may explain
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at least part of the cases of metronidazole resistance described in
literature. We did not detect pCD-METRO in the sequence read
archive in entries labeled as C. difficile, or otherwise.
Our observations above raise the question how prevalent pCD-
METRO is in MTZR C. difficile isolates and if there is a bias
towards specific types or geographic origins. As metronidazole
resistance in C. difficile is rare, we expanded our collection of
clinical isolates through our network (including the ECDC) (n=
76) and with selected strains from the Tolevamer (n= 42) and
MODIFY (n= 46) clinical trials44–46. To correct for interlabora-
tory differences in typing and antimicrobial susceptibility testing,
all strains were retyped by ribotyping and tested for metronida-
zole resistance using agar dilution according to Clinical &
Laboratory Standards Institute (CLSI) guidelines in our labora-
tory with inclusion of appropriate control strains47,48. Although
these strains, with the exception of the Tolevamer strains, were
characterized as having altered metronidazole susceptibility by
the senders (n= 122), agar dilution performed in our own
laboratory classified nearly all of these strains as metronidazole
susceptible (MIC < 2mg L−1). We expected pCD-METRO to be
present in MTZR strains, but not in MTZS strains.
We identified three additional metronidazole-resistant strains: a
RT027 isolate from Poland (LUMCMM19 0960; MIC > 8mg L−1),
a RT010 isolate from the Czech Republic (LUMCMM19 0880;
MIC > 8mg L−1) and a RT010 isolate from Germany (P016134;
MIC > 8mg L−1) (Table 1). A PCR on PSD-treated chromosomal
DNA isolated from these strains yielded a positive signal using
primers targeting the plasmid, but not the chromosome (Fig. 3,
lanes PL/CZ/DE), demonstrating all three strains contain pCD-
METRO. WGS showed that pCD-METRO in strain LUMCMM19
0960 was identical to that of strain IB136, whereas LUMCMM19
0880 contained a single SNP resulting in a D131N substitution in
ORF1 (Supplementary Figure 1). We also screened our laboratory
collection of RT010 strains from human and animal sources and
identified seven more MTZR strains (as determined by both agar
dilution and epsilometer tests [E-test]), six of which were positive
for pCD-METRO (86%; Supplementary Data 1). A single
RT010 strain (LUMCMM19 0830) tested MTZR resistant in agar
dilution according to CLSI guidelines (MIC= 4 mg L−1)47, but
this strain was negative for pCD-METRO in both PCR and WGS.
Using E-tests, we found this strain to be susceptible to
metronidazole (MIC= 0.19 mg L−1) when grown on standard
laboratory Brain-Heart Infusion (BHI) agar but resistant (MIC=
16mg L−1) on Brucella Blood Agar (BBA), suggesting a
contribution of medium components (possibly heme) to the
resistance phenotype (Fig. 4). On both media RT010 control
strains IB138 and IB140 are resistant and susceptible, respectively
(Fig. 4), with 2–4-fold differences in MIC between the medium
conditions. Thus, all pCD-METRO containing strains in this study
show medium-independent metronidazole resistance with a
Table 1 Strains described in this study.
Name Characteristics PCR ribotypea Toxin profileb MTZ resistancec Source Reference
630Δerm Wild type 012 A+ B+ CDT- 0.125 (S) Laboratory 49
IB125 630Δerm pIB86 (pCD-METROshuttle);
thiR
012 A+ B+ CDT- ≥8 (R) Laboratory This study
IB132 pCD-METRO− 020 A+ B+ CDT- 0.25 (S) Human This study
IB133 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB134 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB135 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB136 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB137 pCD-METRO – 078 A+ B+ CDT+ 0.125 (S) Human This study
IB138 pCD-METRO + 010 A- B- CDT- >8 (R) Human This study
IB139 pCD-METRO – 010 A- B- CDT- 1 (S) Human This study
IB140 pCD-METRO – 010 A- B- CDT- 0.25 (S) Human This study
IB141 pCD-METRO – 010 A- B- CDT- 0.125 (S) Human This study
IB142 pCD-METRO – 010 A- B- CDT- 0.125 (S) Human This study
IB143 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB144 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB145 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB146 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB147 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB148 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB149 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB151 (P016134) pCD-METRO + 010 A- B- CDT- >8 (R) Unknown 81
IB30 630Δerm pIB20 (pCD6 replicon,
PCD0716-slucopt); thiR
012 A+ B+ CDT- 0.25 (S) Laboratory This study
IB90 630Δerm pIB80 (pCD-METRO replicon,
Ptet-gusA); thiR
012 A+ B+ CDT- 0.125 (S) Laboratory This study
LUMCMM18 0002 pCD-METRO – 020 A+ B+ CDT- ND (S) Human This study
LUMCMM19 0348 pCD-METRO + 020 A+ B+ CDT- ND (R) Human This study
LUMCMM19 0830 pCD-METRO – 010 A- B- CDT - 4 (R) Unknown This study
LUMCMM19 0880 pCD-METRO + 010 A- B- CDT- >8 (R) Unknown This study
LUMCMM19 0970
(7032989)
pCD-METRO + 010 A- B- CDT- >8 (R) Unknown 29
LUMCMM19 0960 pCD-METRO + 027 A+ B+ CDT+ >8 (R) Human 46
Listed are strains mentioned in the main body of the manuscript. For a complete overview of all strains used, see Supplementary Data 1.
thiR thiamphenicol resistance, S susceptible (MIC < 2mg L−1), R resistant (MIC > 2mg L−1) based on the EUCAST epidemiological cutoff for metronidazole32, ND not determined by agar dilution, but only
by E-test (Supplementary Fig. 2).
aPCR ribotype determined at the LUMC standard PCR ribotyping.
bToxin profile determined by multiplex PCR.
cMetronidazole MIC values in mg L−1 as determined by agar dilution conform CLSI guidelines.
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MIC ≥ 8mg L−1 in agar dilution (22/22). By contrast, all
susceptible isolates (n= 563) lacked pCD-METRO.
Taken together, our results show that pCD-METRO is
internationally disseminated and can explain metronidazole
resistance in both non-toxigenic- and toxigenic isolates of
C. difficile, including those belonging to epidemic ribotypes such
as RT027.
pCD-METRO is likely acquired via horizontal gene transfer.
Our whole-genome sequence analysis suggested the acquisition of
pCD-METRO by a toxigenic RT020 strain during treatment of
rCDI. We made use of longitudinal fecal samples that were stored
during treatment to investigate the presence of pCD-METRO in
total fecal DNA at various timepoints. Total DNA derived from
the fecal sample harboring the MTZS RT020 was positive for the
presence of pCD-METRO (Fig. 5). This indicates that pCD-
METRO was present in the gut reservoir of the patient. Post-
FMT, pCD-METRO was no longer detected in total fecal DNA,
suggesting that the fecal transplant reduced levels of pCD-
METRO containing C. difficile and/or the donor organism to
below the limit of detection of the assay. Fecal samples were
stored in the absence of cryoprotectant and as a result we were
unable to reculture the possible donor organism.
Although we cannot exclude the possibility that the MTZR
RT020 strain was already present at the moment the MTZS
RT020 strain was isolated, our results indicate that pCD-METRO
was most likely acquired through horizontal gene transfer
between the MTZS C. difficile strain and an as-of-yet unchar-
acterized donor organism in the gut of the patient.
PCR-based identification of metronidazole-resistant strains.
We implemented a PCR targeting pCD-METRO in our routine
surveillance and ad hoc typing, as part of the Dutch National
Reference Laboratory (NRL) for C. difficile. In the period
February-August 2019, we characterized 721 strains by ribotyp-
ing, and identified a single pCD-METRO-positive strain
(LUMCMM19 0348) by PCR. These preliminary data suggest a
prevalence of <0.14% in an endemic setting in the Netherlands.
The identified strain belonged to RT020 and was confirmed to be
MTZR in an E-test on BBA (Supplementary Fig. 2). As described
for the patient case above, we were able to identify an earlier
RT020 isolate from the same patient (LUMCMM18 0002) that
was pCD-METRO negative and MTZS (Supplementary Fig. 2).
WGS revealed that the susceptible and resistant strains were
identical (0 SNPs difference), but differed as expected in carriage
of pCD-METRO. pCD-METRO in the MTZR isolate contained
two SNPs compared to the plasmid of strain IB136; a G > A
conversion located intergenically between ORF6 and ORF7, and a
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Fig. 2 pCD-METRO is a 7-kb plasmid. a Structure of plasmid pCD-METRO and its ORFs. The two innermost circles represent GC content (outer circle)
and GC skew (innermost circle) (both step size 5 nt and window size 500nt;, above average in yellow, below average in purple). The unique HaeIII site used
to construct pCD-METROshuttle (see methods) is indicated. b Gene-specific PCR products amplifying regions of ORFs 6 (lane 1+ 2), ORF5 (lane 3), ORF7
(lane 4) and ORF3 (lane 5), and a chromosomal locus (gluD) (c) The product of plasmid-specific amplification (targeting ORF6, pCD) or chromosomal-
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Fig. 3 pCD-METRO is internationally disseminated. PCR analysis of strains 7032989 (RT010, Spain) (SP), LUMCMM190960 (RT027, Poland) (PL),
LUMCMM19 0880 (RT010, Czech Republic) (CZ), and P016134 (RT010, Germany) (DE). The product of plasmid-specific amplification (targeting ORF8)
or chromosomal-specific amplification (gluD) before and after PlasmidSafe DNase treatment are shown. Source data are provided as a Source Data file.
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Our data suggests that selection by metronidazole is crucial
in the acquisition of, or selection for, pCD-METRO containing
C. difficile.
pCD-METRO confers metronidazole resistance in C. difficile.
Above, we have clearly established a correlation between the
presence of pCD-METRO and metronidazole resistance. Next, we
sought to unambiguously demonstrate that acquisition of pCD-
METRO, and not any secondary events, lead to metronidazole
resistance. To generate isogenic strains with or without pCD-
METRO, we introduced a shuttle module in the unique HaeIII
restriction site of the plasmid and introduced the resulting vector,
pCD-METROshuttle (pIB86; Supplementary Fig. 3), into the
RT012 laboratory strain 630Δerm using standard methods49.
Metronidazole E-tests showed a reproducible 15-to-20-fold
increase in the MIC from 0.064/0.19 mg L−1 for the strain
without pCD-METROshuttle to 2–4 mg L−1 for the strain with
pCD-METROshuttle (Fig. 6). These results were confirmed using
agar dilution, that showed a > 24-fold increase (>5 doubling
dilutions) from 0.125-0.25 mg L−1 to 8 mg L−1 or higher upon
introduction of pCD-METROshuttle (Table 1).
As controls, we included the MTZS (IB132) and a MTZR
(IB133) RT020 strain isolated from the patient. In agreement with
the MIC values determined by agar dilution (MIC= 0.25 mg L−1
and MIC= 8 mg L−1), these isolates showed a MIC correspond-
ing to those observed for the MTZS and MTZR RT012 isolates,
respectively (Fig. 6).
Overall, our results show that acquisition of pCD-METRO is
sufficient to raise the MIC of C. difficile to values greater than the
epidemiological cutoff value defined by EUCAST32.
pCD-METRO contains a high copy-number replicon. Read
depth of pCD-METRO in our WGS data indicates an estimated
copy number of 100–200, in stark contrast with the pCD6
replicon commonly used in shuttle vectors for C. difficile (copy
number 4–10)50. We wanted to establish the functionality of the
predicted replicon and determine the copy number sustained by
this replicon in RT012 strains.
A pRPF185-based vector51 (pIB80) was constructed in which
the conventional pCD6 replicon was replaced by a 2-kb DNA
fragment of pCD-METRO that includes ORF5, encoding the
putative replication protein (Supplementary Fig. 4). Transconju-
gants containing this vector were readily obtained in the RT012
laboratory strain 630Δerm, demonstrating this region contains a
functional replicon.
Next, we compared the relative copy number of the plasmids in
overnight cultures by quantitative PCR (qPCR)50. Based on the
ratio of plasmid-locus catP to the chromosomal locus rpoB, the
copy number of pCD6-replicon vector was ~4, concordant with
results of others50. By contrast, the copy number of vectors with
the pCD-METRO replicon ranges from ~25 (for pIB80, in IB90) to
38 (pCD-METROshuttle, in IB125) (Fig. 7a). We hypothesized that
a higher plasmid copy number would also lead to more copies of
the resistance marker on the plasmid and thus to a possible
increase of resistance to the corresponding antibiotic. Indeed, a












Fig. 4 Medium-dependent metronidazole resistance. Strains were grown as described under antimicrobial susceptibility testing in the Methods section
and spread onto either Brucella Blood Agar (BBA) plates, or onto BHIY/CDSS agar plates (BHI). E-tests were placed, and plates were incubated for 48 h
before imaging. In all, 2 mg L−1 is the EUCAST epidemiological cutoff for metronidazole that was used to define resistance in this study32. E-test values for
the indicated strains are shown next to their respective panels. The images represent three independent repeats with a single replicate per condition.
Source data are provided as a Source Data file.
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Fig. 5 pCD-METRO is detectable in fecal total DNA. pCD-METRO is
detectable in fecal total DNA from the same sample from which a MTZS
RT020 C. difficile was isolated. Shown are the results from a PCR targeting
ORF6, but similar results were obtained for other plasmid-specific primer
sets. Source data are provided as a Source Data file.
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replicon demonstrates a growth advantage over a strain harboring
a similar plasmid with the pCD6 replicon when exposed to high
levels (256mg L−1) of thiamphenicol. No significant difference in
growth was observed at low concentrations (20mg L−1) of
thiamphenicol (Fig. 7b). As pIB80 containing strains are not
MTZR (Fig. 6), resistance to metronidazole is not mediated by a
higher copy number plasmid per se, but is dependent on a























Fig. 6 pCD-METRO confers metronidazole resistance. RT020 without plasmid (MTZS, strain IB132), RT020 with pCD-METRO (MTZR, strain IB133),
RT012 without plasmid (MTZS, strain 630Δerm), RT012 with pIB86 (pCD-METROshuttle, MTZR, strain IB125), RT012 with pIB80 (MTZS, IB90; pIB80
contains the pCD-METRO replicon but lacks the other ORFs of pCD-METRO). IB90 and IB125 are 630Δerm-derivatives49. E-tests were performed on BHI
agar plates with CDSS. Identical results were obtained on plates without CDSS. The images represent three independent repeats with a single replicate per
condition. In all, 2 mg L−1 indicates the EUCAST epidemiological cutoff for metronidazole that was used to define resistance in this study32. E-test values































Strain - [thi] 
AP38 - 0 mg L–1
AP38 - 20 mg L–1
AP38 - 256 mg L–1
IB90 - 0 mg L–1
IB90 - 20 mg L–1
IB90 - 256 mg L–1
b
Fig. 7 The pCD-METRO replicon sustains a high plasmid copy number. a 630Δerm is the wild type RT012 laboratory strain. IB30: 630Δerm+ pIB20
(contains pCD6 replicon); IB90: 630Δerm+ pIB80 (contains pCD-METRO replicon); IB125: 630Δerm+ pCD-METROshuttle (pIB86, contains pCD-METRO
replicon). Copy number is determined as the ratio of a plasmid locus (catP) relative to a chromosomal locus (rpoB) as determined by qPCR on total DNA.
Data from strains containing a plasmid with the pCD6-replicon are indicated in blue, data from strains containing a plasmid with the pCD-METRO replicon
are indicated in red. Individual data points are plotted using symbols. Horizontal lines indicate median values. 630Δerm vs IB30: P= 0.1018; IB90 vs. IB125:
P= 0.0002; other comparisons: P < 0.0001 as determined by two-sided ANOVA and Tukey’s test. Experiments were performed in triplicate on three
different technical replicates. b A strain derived from the laboratory RT012 strain 630Δerm harboring a plasmid containing the pCD-METRO replicon
(IB90) has a growth advantage over a strain containing a plasmid with the pCD6 replicon (AP38) when cultured at high levels of thiamphenicol (thi). AP38:
630Δerm+ pAP24 (pCD6 replicon); IB90: 630Δerm+ pIB80 (pCD-METRO replicon). Growth is measured as an increase in optical density at 600 nm
(OD600). Solid line indicates the mean of the individual measurements that are shown using dots (n= 3 biologically independent samples). Source data
are provided as a Source Data file.
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A difference between the read-depth estimate and the qPCR
can be explained by technical bias or differences in strain
background. Nevertheless, our experiments clearly demonstrate
that the pCD-METRO replicon sustains plasmid levels that are
~10-fold greater than that of currently used replicons.
We investigated whether the relatively high copy number of
pCD-METRO imposes a metabolic cost, by evaluating the growth
of strains with and without plasmid in the absence or presence of
varying concentrations of metronidazole (Fig. 8). In the absence
of metronidazole, the growth of susceptible and resistant strains
of both RT012 and RT020 is indistinguishable (Fig. 8a). This was
not due to loss of pCD-METRO from the resistant strain, as all
colonies tested after the growth experiment had retained the
plasmid. With increasing amounts of metronidazole, susceptible
strains show a clear growth defect already at the lowest
concentration of metronidazole tested (0.125 mg L−1), whereas
resistant strains do not markedly differ in growth from the
control culture at concentrations below the epidemiological cutoff
(2 mg L−1) (Fig. 8b, c). These values are in agreement with the E-
tests performed on the same media (Fig. 6). We conclude that
carriage of the plasmid does not affect growth rate in the absence
of metronidazole, despite the high copy number, and confers a
clear growth advantage in the presence of metronidazole.
We attempted to cure metronidazole-resistant strains of pCD-
METRO using serial passaging on non-selective liquid or solid
medium. Despite our efforts (Supplementary Methods), we failed
to obtain colonies that lacked pCD-METRO, even after non-
selective culturing for >50 generations. We hypothesize that the
high copy number of pCD-METRO contributes to its stability.
Altogether, these results demonstrate that pCD-METRO encodes
a functional replicon that is responsible for a high copy number in
C. difficile and is efficiently maintained in the absence of selection.
Discussion
In this study, we describe a plasmid linked to resistance against a
clinically relevant antimicrobial in C. difficile. We show that the
high copy number plasmid pCD-METRO is internationally dis-
seminated, present in diverse PCR ribotypes—including those
known to cause outbreaks—and we provide evidence for the
possible horizontal transmission of the plasmid. Our data sug-
gests a possible prevalence of <0.14% (1/721; endemic) to 3.9%
(22/563; collection enriched for metronidazole-resistant strains)
of the plasmid, in line with previous observations52.
Although the presence of plasmids in C. difficile has been
known for many years, no phenotypes associated with plasmid
carriage have been described39,41,53. We show that introduction
of pCD-METRO in susceptible strains leads to stable and
medium-independent metronidazole resistance. Plasmids may
play a broader role in antimicrobial resistance of C. difficile. A
putative plasmid containing the aminoglycoside/linezolid resis-
tance gene cfrC was recently identified in silico, but in contrast to
our work no experiments were presented to verify the contig was
in fact a plasmid conferring resistance54. The presence of an
antimicrobial resistance gene does not always result in resistance,
and DNA-based identification of putative resistance genes with-
out phenotypic confirmation may lead to an overestimation of the
resistance frequencies19,55,56.
At present, it is unknown which gene(s) on pCD-METRO are
responsible for metronidazole resistance. Nitroimidazole reduc-
tase (nim) genes have been implicated in resistance to nitroimi-
dazole type antibiotics27. Although the presence of a truncated
nim gene on pCD-METRO is intriguing, we do not believe this
gene to be responsible for the phenotype for several reasons.
Structural modeling of the predicted protein shows that it lacks
the catalytic domain, and introduction of the ORF under the
control of an inducible promoter (Supplementary Data 1 and
Supplementary Table 2) did not confer resistance in our labora-
tory strain. Moreover, the RT027 strain R20291 encodes a puta-
tive 5-nitroimidazole reductase (R20291_1308) and is not
resistant to metronidazole, implying the presence of a nim gene is
not causally related to metronidazole resistance in C. difficile as
also noted by others27. Further research is necessary to determine
the mechanism for metronidazole resistance in C. difficile con-
ferred by pCD-METRO, and to investigate the contribution of the
high copy number (Fig. 6) to the resistance phenotype.
Our work, combined with that of others, suggests that metro-
nidazole resistance is multifactorial and other factors than pCD-
METRO can cause or contribute to metronidazole resistance in C.
difficile. For instance, pCD-METRO may not explain low level
resistance, heterogeneous resistance, or stable resistance resulting
from serial passaging of isolated strains under metronidazole
selection27,29,36,57. We also observed that absolute MIC values in
agar dilution experiments differed between MTZR isolates of dif-
ferent PCR ribotypes despite carriage of pCD-METRO, suggesting
a contribution of chromosomal or other extrachromosomal loci to
absolute resistance levels. Although the SNP we identified in the
RT020 strain IB136 was not found in other MTZR strains of
RT010/RT020/RT027, we cannot exclude that it contributes to the
resistance in this particular strain. We also observed strong
medium-dependent effects: the MICs obtained on BBA are gen-
erally higher than those on BHI (Fig. 4), underscoring the
importance of using standard conditions for susceptibility testing.
Notably, for at least one RT010 strain (LUMCMM19 0830) this
led to conversion of the resistance phenotype. Clearly, medium
components (possibly iron or heme) contribute to metronidazole
resistance. This is in line with suggested metabolic changes in
MTZR strains that do not harbor pCD-METRO29,30,36.
The pCD-METRO plasmid is internationally disseminated
(Table 1 and Fig. 3), although further research is necessary to
determine how prevalent the plasmid is in metronidazole-
resistant C. difficile isolates. This study attempted to enrich
for metronidazole-resistant strains as this resistance is scarce in
C. difficile. We received strains that were reported to be
metronidazole-resistant by the senders. However, when performing
antimicrobial susceptibility testing for these strains with agar dilu-
tion in our own laboratory, virtually all strains had MIC values
below the epidemiological cutoff value from EUCAST for metro-
nidazole and were considered susceptible. For this reason, we ended
up having very few metronidazole-resistant isolates of other PCR
ribotypes than RT010 (RT020 and RT027). It is not entirely clear
how these differences came into existence. Depending on handling
of the sample material and freeze-thawing cycles, it is possible that
inducible metronidazole resistance, unrelated to pCD-METRO, was
initially measured and that this was lost after storage and lack of
selection36. Considering the apparent stability of pCD-METRO, we
do not think that the discrepancies are due to loss of the plasmid
during passaging on non-selective media.
Based on the apparent stability of the pCD-METRO plasmid,
we consider acquisition rather than loss of pCD-METRO a more
likely explanation for the clonality of the RT020 patient isolates.
As C. difficile has not been demonstrated to be naturally com-
petent for transformation, this suggests that pCD-METRO may
be transmissible. Horizontal gene transfer is consistent with the
observed level of sequence conservation between the RT010,
RT020, and RT027 pCD-METRO plasmids sequenced in this
study (Supplementary Fig. 1). Nevertheless, we failed to demon-
strate intraspecies transfer with different donor and recipient
strains of C. difficile under laboratory conditions (Supplementary
Methods), suggesting that the strains tested (or possibly the
species) lack a determinant required for transfer. Together with
its size and the presence of mobilization genes (Fig. 2a), we
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therefore hypothesize that pCD-METRO is mobilizable from an
uncharacterized donor organism58. We screened the complete
sequence read archive of the NCBI (paired-end Illumina data) for
potential sources of the plasmid, but failed to identify any entries
with reliable mapping (>1% of data) to pCD-METRO.
As more reports are published associating metronidazole with
higher treatment failure31, a shift in consensus for using metro-
nidazole as first-line treatment for mild to moderate CDI is
occurring59. The reason for treatment failure is currently
unknown, but no correlation between MTZR C. difficile isolates
and treatment failure seems to exist.55 We also observed that
clinical isolates from subjects in which metronidazole treatment
failed, were metronidazole susceptible and pCD-METRO negative
(Supplementary Data 1)45. These observations, however, do not
rule out a role for (other) metronidazole-resistant organisms,
potentially harboring pCD-METRO, in treatment failure. Indeed,
levels of metronidazole at the end of the colon and in fecal
material are low (most likely due to absorption of the drug in the
small intestine in the absence of diarrhea)31, and members of the
microbiota involved in inactivation or sequestering of metroni-
dazole may allow for growth of MTZS species60–63.
Our observation of a putatively transmissible plasmid associated
with metronidazole resistance in C. difficile and the gut micro-
biome has implications for clinical practice. First, it warrants a
further investigation into the role of the plasmid in metronidazole
treatment failure in CDI, and—more broadly—in metronidazole
resistance of organisms other than C. difficile. Second, though this
work can be seen as one more argument against the use of
metronidazole as a first-line treatment of CDI, detection of



















































































Fig. 8 The effects of carriage of pCD-METRO on growth. a Growth as monitored by an increase in optical density at 600 nm (OD600) of various strains
in the absence of metronidazole. b Growth of RT012 strains in the presence of various concentrations of metronidazole [mtz]. c Growth of RT020 strains in
the presence of various concentrations of metronidazole [mtz]. Individual measurements are shown as semi-transparent dots. The median of the replicates
is shown as a solid line. Source data are provided as a Source Data file.
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(i.e., pCD-METRO harboring patients are excluded from metro-
nidazole treatment). And finally, screening by PCR of fecal donor
material intended for FMT might be desirable to reduce the pos-
sibility of transferring pCD-METRO from hitherto uncharacterized
donor organisms to C. difficile in patients.
Methods
Strains. The strains sequenced as part of this study come from various sources.
Twenty-one strains were isolated from a single patient at the Leiden University
Medical Center (LUMC) or derived from the collection of human and animal
isolates of the Dutch NRL for C. difficile, which is hosted at the LUMC. Informed
consent (approved by the Medical Ethical Committee of the LUMC) was given for
the use of the patient samples for research purposes. Other clinical isolates (n=
567) were obtained through the NRL and partners in the C. difficile typing network
of the European Center for Disease Prevention and Control (ECDC), or were
previously collected as part of the ECDIS study and the Tolevamer and MODIFY I
+ II clinical trials44–46—two of these were also sequenced. Strain IB136, for which
the genome sequence is available from the European Nucleotide Archive (accession
CAADHH010000000) has been deposited in the National Collection of Type
Cultures (NCTC14385) of Public Health England.
Whole-genome sequencing and analysis. DNA was extracted from 9mL of
stationary growth phase cultures grown in BHI (Oxoid) broth using a QIA-
symphony (Qiagen, The Netherlands) with the QIAsymphony DSP Virus/Patho-
gen Midi Kit according to the manufacturer’s instructions. All samples were
sequenced on an Illumina HiSeq4000 (all samples except those mentioned here-
after) or NovaSeq (LUMCMM18 0002, LUMCMM19 0348, LUMCMM19 0880
and LUMCMM19 0960) platform with read length 150 bp in paired-end mode. All
C. difficile samples isolated from the patient were assembled using an in-house
pipeline, which includes various QC and comparative measures, assembly with six
different assemblers as well as scaffolding, but which are not used for all steps and
assemblers. Ultimately, Edena v3.131028 was used on the non-trimmed reads with
an overlap range between 76 and 14664. Reads were mapped back to all assemblies
for quality control purposes with Bowtie2 v2.3.1, and SAM files were converted to
sorted and indexed BAM files with Samtools v1.5 to obtain mapping rates to the
assembly65,66. After this step, all contigs from assemblies with a length smaller than
304 bp were discarded, as well as contigs corresponding to the phiX phage spike in
(GenBank accession number J02482.1). To remove contaminating contigs, contigs
from all assemblies were compared with Blastn v2.6 against the NCBI database
(download 10 July, 2018, standard parameters, except e-value of 0.0001)67,68.
Taxonomy was estimated with the Lowest Common Ancestor algorithm as
implemented in MEGAN, except that only Blast matches with a minimum length
of 100 bp, and as well only matches not deviating more than 10% in length from
the longest match were considered69. Filtering was performed on phylum level and
the dominant phylum was determined by the amount of base pairs in the assigned
blast matches. All contigs assigned to another phylum were discarded. For quality
control, the expected genome size was estimated with kmerspectrumanalyzer
download August 2013 and Jellyfish v1.1.1170,71. Using bedtools genomecov
v2.2.16 the read coverage of the assemblies were calculated72. All sequence ranges
larger than 20 bp with less than 50% coverage and with a larger distance than
200 bp from the contig end were manually inspected, unless only Ns were con-
tained in the sequence. Final evaluation was performed with the values for N50,
assembly size (in relation to predicted genome size), mapping rate and manual
inspection of low coverage sites. The assembly being evaluated as being best was
performed with the Edena assembler and an overlap of 126 (IB136) or 136
(LUMCMM19 0348), with contamination and length filtering, without additional
scaffolding and gapfilling.
Annotation was performed with an in-house pipeline as described before41.
This annotation was furthermore manually reviewed and the annotations from the
assembly of C. difficile 630 (based on Blastn comparison on gene level) were
transferred where applicable.
Extrachromosomal elements were predicted as described before40,41. To identify
plasmids similar to the pCD-METRO, a homology search was performed with
Blastn (with an e-value of 0.0001). A further search for non-assembled plasmid
sequences was performed. All samples sequenced in paired-end mode on Illumina
machines were downloaded from the NCBI with eutils prefetch, and mapped to the
plasmid sequence with bowtie2 v2.3.1 to the plasmid sequence. The option–no-
mixed was used to supress incorrectly mapping pairs68.
SNP typing was performed after selecting the best reference assembly. The SNP
typing was performed with the in-house pipeline Basty based on the biopet
framework73. This pipeline performs mapping to the reference assembly with
bowtie2 v2.3.1 and SNP typing with BCFtools v1.1-13474. Groups were investigated
for homozygous SNPs differentiating them. Heterozygous SNPs were discarded.
Genomic comparisons between assemblies were performed with Blastn (standard
parameters, except an e-value of 0.0001). All programs were executed with
standard parameters unless otherwise specified.
Multi-locus sequence type was determined using stringMLST v0.6.275 with
default settings.
Antimicrobial susceptibility testing and ribotyping. All strains were character-
ized by standardized PCR ribotyping and tested multiple times for metronidazole
resistance by agar dilution according to CLSI guidelines, with the inclusion of
appropriate microbiological controls47,48. No formal breakpoints have been defined
for metronidazole resistance in C. difficile; here we use the EUCAST epidemiolo-
gical cutoff of 2 mg L−1 to define resistance32. Details of all strains and their
characteristics are available in Table 1 and Supplementary Data 1. For E-tests
(BioMerieux), bacterial suspensions corresponding to 1.0 McFarland turbidity were
applied on BHI agar supplemented with 0.5% yeast extract (Sigma-Aldrich) and
Clostridium difficile Selective Supplement (CDSS, Oxoid) or on Brucella Blood
Agar plates without antimicrobials. MIC values were read after 48 h of incubation
as recommended by CLSI47.
Molecular biology techniques. Escherichia coli was cultured aerobically at 37 °C
in Luria–Bertani (LB) broth, supplemented with 20 mg L−1 chloramphenicol and
50 mg L−1 kanamycin when appropriate. C. difficile was cultured in BHI supple-
mented with 0.5% yeast extract, CDSS and 20 mg L−1 thiamphenicol when
appropriate, in a Don Whitley VA-1000 workstation (10% CO2, 10% H2 and 80%
N2 atmosphere).
Plasmids and oligonucleotides are listed in Supplementary Tables 1 and 2,
respectively. pIB86 (pCD-METROshuttle, Supplementary Fig. 3 and Supplementary
File 1) was constructed using Gibson assembly using HaeIII-linearized pCD-
METRO and a fragment from pRPF185 (Addgene 106367)51. This fragment was
obtained by PCR, and contained the requirements for maintenance in, and transfer
from, E. coli. Cesium chloride purified pCD-METRO (see below) was linearized
using restriction endonuclease HaeIII. Primers oWKS-1663 and oWKS-1664
annealed on pRPF185 generating a PCR shuttle-fragment containing pBR322ori-
catP-oriT-traJ. To assemble pIB86, 100 ng of insert was assembled against a
fourfold molar excess of linearized pCD-METRO backbone using a homemade
Gibson Assembly Master Mix (4 U μL−1 Taq Ligase (Westburg), 0.004 U μL−1 T5
exonuclease (New England Biolabs), 0.025 U μL−1 Phusion polymerase (Bioké), 5%
polyethyleneglycol (PEG-8000), 10 mM MgCl2, 100 mM Tris-Cl pH= 7.5, 10 mM
dithiothreitol, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dCTP, 0.2 mM dGTP, and
1 mM β-nicotinamide adenine dinucleotide) for 30 min at 50 °C and transformed
into MDS42 cells76,77. Transformants were screened by colony PCR using primers
oBH-5 and oWKS-1387. The entire sequence of pIB86 was verified by Sanger
sequencing using primers oBH-1, oBH-5, oBH-6, oBH-8, oBH-9, oBH-10, oBH-11,
oBH-12, oIB-120-, oIB-121, and oIB-122, oWKS-1241-, oWKS-1383, oWKS-1388,
oWKS-1537, oWKS-1539, oWKS-1540, oWKS-1574, oWKS-1656, oWKS1658,
oWKS-1659, oWKS-1661, oWKS-1663, oWKS-1664 and oWKS-1678. Plasmid
pIB80 (Supplementary Fig. 4 and Supplementary File 2) was constructed by ATUM
(Newark, CA) and contains a pCD-METRO derived fragment inserted in between
the KpnI and NcoI sites of pRPF18551.
Transfer of plasmids from E. coli CA434 to C. difficile 630Δerm49 was done
using standard methods78. Routine DNA extractions were performed using the
Nucleospin Plasmid Easypure (Macherey-Nagel) and DNeasy Blood and Tissue
(Qiagen) kits after incubating the cells in an enzymatic lysis buffer according to
instructions of the manufacturers.
Isolation of cloning-grade pCD-METRO. Plasmid pCD-METRO was extracted
from 400 mL of culture containing the MTZR strain IB138 using the Macherey-
Nagel Nucleobond Xtra Midi kit. Using the CsCl2 plasmid purification method this
plasmid prep was further cleaned as summarized hereafter. pCD-METRO plasmid
prep was added to TE buffer (10 mM Tris pH= 8.0, 1 mM EDTA) and CsCl2 was
added to a density of 1 g g−1. Approximately 220 µg mL−1 ethidium bromide was
added to this solution after which samples were spun down in a Beckman Coulter
Optima XE-90 ultracentrifuge for 17 h at 65,000 rpm, 20 °C. Bands were visualized
with ultraviolet (UV) light and plasmid DNA was collected by withdrawing the
lowest of the two resulting bands with an 18 gauge needle. To remove ethidium
bromide 1x vol/vol 5 M NaCl saturated N-butanol was used to remove the upper
(purple) phase after centrifugation. Samples were ethanol precipitated twice prior
to resuspending purified plasmid DNA in TE buffer.
Plasmid copy number determination. Real-time quantitative PCR (qPCR)
experiments were performed essentially as described50. In short, total DNA was
isolated after 17 h of growth using a phenol-chloroform extraction protocol and
diluted to a concentration of 10 ng µL−1. Four microliters of the diluted DNA
sample was added to 6 µL of a mixture containing SYBR Green Supermix (Bio-
Rad) and gene-specific primers (0.4 µM total) for a total volume of 10 µL per well.
Gene-specific primers used were targeting rpoB (chromosome) and catR (plasmid)
and copy number was calculated using the ΔCT method. Experiments were per-
formed in triplicates on three different technical replicates. Statistical significance
was calculated using two-way analysis of variance (ANOVA) and Tukey’s test for
multiple comparisons (Prism 8, GraphPad)(Supplementary Table 3).
Preparation of figures. Agarose gel and E-test images were acquired using a Bio-
Rad GelDoc XR, processed in Adobe Photoshop CC 2018 (Adobe). Plasmid
maps were generated using Artemis and DNAplotter79,80. Graphs were generated
using PlotTwist (https://huygens.science.uva.nl/PlotTwist/) and PlotsOfData
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(https://huygens.science.uva.nl/PlotsOfData/). All figures were prepared for pub-
lication in Adobe Illustrator CC 2018 (Adobe).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data that support the findings of this study are available in the European
Nucleotide Archive under BioProject number PRJEB24167 with accession numbers
ERR2232520-ERR2232537, ERR3611150-ERR3611153, and ERR3772426. The annotated
genome assembly for IB136, including pCD-METRO, can be found under accession
number CAADHH010000000 and as Supplementary Data 2. The source data underlying
Figs. 1, 2b, c, 3–8 and Supplementary Fig. 2 are provided as a Source Data file.
Code availability
Computer code related to the analysis from this paper is based on published tools, as
described in the Methods, and details are available from the authors on request.
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